RenovoRx (RNXT)
NASDAQ:RNXT
Top Page
RenovoRx
(NASDAQ:RNXT)
Select Model
Select Model
Rating:55Neutral
Price Target:
$0.92
▼(-1.81% Downside)
Action:ReiteratedDate:03/31/26
The score is held back mainly by weak financial performance (large ongoing losses and cash burn versus a small revenue base). Offsetting this are improving technical momentum and generally positive operational/clinical progress, supported by recent financing, though listing compliance risk remains a headwind.
Positive Factors
Commercial traction (RenovoCath)
Clear commercial adoption across academic and community centers signals durable demand for the RenovoCath device. A growing approved-center base and repeat physician use create a foundation for recurring device sales and predictable multi-quarter revenue scaling despite a long hospital sales cycle.
Negative Factors
High cash burn
Sustained negative operating and free cash flows indicate the business consumes material capital to advance trials and commercialization. Even if accounting losses track cash, the persistent burn requires external financing, constraining autonomy and increasing refinancing and dilution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial traction (RenovoCath)
Clear commercial adoption across academic and community centers signals durable demand for the RenovoCath device. A growing approved-center base and repeat physician use create a foundation for recurring device sales and predictable multi-quarter revenue scaling despite a long hospital sales cycle.
Read all positive factors
RenovoRx (RNXT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$42.30M
Dividend YieldN/A
Average Volume (3M)288.82K
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue GrowthN/A
EPS Growth37.89%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding45,052,708
10 Day Avg. Volume236,040
30 Day Avg. Volume288,821
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)5.47
Price to Sales (P/S)26.43
P/FCF Ratio-2.70
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue23.18
Enterprise Value/Gross Profit32.71
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$6.75Price Target Upside618.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$3.68M
RenovoRx Business Overview & Revenue Model
Company Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and Reno...
How the Company Makes Money
null...
RenovoRx Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Positive
RenovoRx's earnings call highlights a strong commercial momentum with the expansion of their TAMP therapy and RenovoCath device, coupled with solid financial health and promising clinical trial progress. Despite being in the early stages of commercialization and facing a long sales cycle, the overall sentiment is positive due to the significant advancements and strategic positioning for future growth.Positive Updates
Expansion of TAMP Therapy
RenovoRx's TAMP therapy is gaining traction with academic medical centers, NCI-designated cancer centers, and large community hospitals. Early signs of clinical adoption are promising, with repeat use by physicians.
Negative Updates
Relatively New Commercial Launch
RenovoCath's commercialization is still in its early stages with minor sales fluctuations and limited staff handling sales.
Read all updates
Q3-2025 Updates
Positive
Negative
Expansion of TAMP Therapy
RenovoRx's TAMP therapy is gaining traction with academic medical centers, NCI-designated cancer centers, and large community hospitals. Early signs of clinical adoption are promising, with repeat use by physicians.
Read all positive updates
Company Guidance
During RenovoRx's Third Quarter 2025 Conference Call, significant guidance was provided regarding both clinical and commercial advancements. The company reported year-to-date revenue of approximately $900,000 through Q3, with expectations of continued revenue growth into 2026. They have expanded from 5 approved centers at the start of 2025 to 14, with a total of 24 centers requesting quotes for their RenovoCath device. The company is focused on a strategic, data-driven expansion, with plans to add additional sales and marketing personnel to bolster their efforts. Clinically, they are progressing with their Phase III TIGER PACT trial, expecting to complete enrollment in early 2026 and anticipate final data by 2027. With over $10 million in cash and cash equivalents as of September 30, 2025, RenovoRx is well-positioned to fund their ongoing commercial and clinical activities. The company is also exploring various financing options to further strengthen its balance sheet.RenovoRx Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.12M | 43.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 796.00K | 43.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.51M | -10.97M | -11.39M | -9.94M | -5.48M |
| Net Income | -11.17M | -8.81M | -10.23M | -9.89M | -6.32M |
Balance Sheet | |||||
| Total Assets | 8.10M | 8.12M | 1.47M | 7.26M | 16.29M |
| Cash, Cash Equivalents and Short-Term Investments | 7.02M | 7.15M | 1.17M | 6.44M | 15.19M |
| Total Debt | 107.00K | 278.00K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.67M | 3.64M | 4.47M | 1.10M | 938.00K |
| Stockholders Equity | 5.42M | 4.48M | -3.00M | 6.16M | 15.35M |
Cash Flow | |||||
| Free Cash Flow | -10.97M | -9.14M | -10.26M | -8.81M | -5.93M |
| Operating Cash Flow | -10.97M | -9.13M | -10.26M | -8.81M | -5.92M |
| Investing Cash Flow | -2.00K | -12.00K | 2.03M | -2.03M | -15.00K |
| Financing Cash Flow | 10.85M | 15.12M | 5.01M | 42.00K | 19.33M |
RenovoRx Technical Analysis
Negative
0.94
Price Trends
0.95
Negative
0.94
Positive
1.06
Negative
Market Momentum
<0.01
Positive
46.61
Neutral
11.25
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNXT, the sentiment is Negative. The current price of 0.94 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 0.95, and below the 200-day MA of 1.06, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.61 is Neutral, neither overbought nor oversold. The STOCH value of 11.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNXT.
RenovoRx Risk Analysis
RenovoRx disclosed 67 risk factors in its most recent earnings report. RenovoRx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
RenovoRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $342.87M | -6.90 | -23.98% | ― | 946.61% | -11.30% | |
55 Neutral | $42.30M | -2.66 | -146.61% | ― | ― | 37.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $19.80M | -0.46 | -191.12% | ― | ― | -24.38% | |
46 Neutral | $55.24M | -4.61 | -10.61% | ― | ― | 45.97% | |
44 Neutral | $114.73M | -3.07 | -75.73% | ― | ― | 4.71% | |
41 Neutral | $25.49M | -1.76 | ― | ― | ― | 31.09% |
* Healthcare Sector Average
RNXT
RenovoRx
0.94
0.15
18.71%
OVID
Ovid Therapeutics
2.60
2.35
919.61%
GRCE
Grace Therapeutics
3.57
1.63
84.02%
JSPR
Jasper Therapeutics
0.71
-3.00
-80.94%
NRSN
Neurosense Therapeutics Ltd.
0.72
-0.27
-27.02%
PEPG
PepGen Inc.
1.66
0.49
41.88%
RenovoRx Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial
Positive
Mar 30, 2026
RenovoRx reported its full-year 2025 results on March 30, 2026, highlighting $1.1 million in RenovoCath revenue in its first full year of commercialization and growing adoption at 12 U.S. cancer centers, with 21 more in the pipeline. The company c...
Business Operations and StrategyPrivate Placements and Financing
RenovoRx Raises $10 Million in Oversubscribed Private Placement
Positive
Mar 23, 2026
On March 17, 2026, RenovoRx entered into securities purchase agreements for an oversubscribed private placement of common stock, pre-funded warrants and milestone-based warrants with institutional investors and company insiders, closing on March 2...
Business Operations and StrategyExecutive/Board Changes
RenovoRx Appoints Veteran Executive Mark Voll as CFO
Positive
Feb 6, 2026
On February 5, 2026, RenovoRx announced the appointment of veteran public company executive Mark Voll as Chief Financial Officer, effective February 1, 2026, bringing more than three decades of financial leadership and IPO and MA experience from m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.